Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinuvel Pharmaceuticals has reported six-month first Phase II positive results of photoprotective drug - afamelanotide, known as Scenesse.
Subscribe to our email newsletter
The double-blind, multicentre, placebo-controlled, randomised CUV030 study was designed to assess the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in reducing phototoxic skin reactions in erythropoietic protoporphyria (EPP) patients.
The results demonstrated that Scenesse was well tolerated and allowed EPP patients to expose their skin to sunlight during the middle of the day and improved their Quality of Life (QoL).
In addition, the trial also showed that the drug is safe and well-tolerated.
Clinuvel CEO Philippe Wolgen said they are pleased with the outcome of this trial as it adds to the evidence that afamelanotide is effective as a prophylactic treatment for EPP in the clinic and allows a better quality of life for patients.